Straits Times Index
3,286.62 -1.13 (-0.03%) Nikkei
37,988.41 +359.93 (+0.96%) Hang Seng
17,626.75 +342.21 (+1.98%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,257.32 -26.95 (-0.04%) CMC Crypto 200
1,389.14 +6.57 (+0.48%)
DexCom, Inc. (DXCM)
After hours:
| Previous close | 137.87 |
| Open | 138.87 |
| Bid | 137.97 x 100 |
| Ask | 138.10 x 100 |
| Day's range | 134.45 - 139.24 |
| 52-week range | 74.75 - 142.00 |
| Volume | |
| Avg. volume | 3,087,224 |
| Market cap | 54.656B |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | 106.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
Dexcom's profit beats estimates on strong glucose monitor demand
Dexcom beat Wall Street expectations for first-quarter profit on Thursday, helped by strong demand for a new version of its continuous glucose monitors, but its shares slid 7% after the bell as annual sales forecast was largely below estimates. The company and rival Abbott currently dominate the market for continuous glucose monitors — the devices that track blood glucose levels every few minutes without the need for finger stick tests. Dexcom's total revenue rose 24% to $921 million for the three months ended March 31, beating analysts' average estimate of $909.24 million, according to LSEG data.
- Zacks
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- GuruFocus.com
DexCom Inc (DXCM) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance
Revenue Growth and Strategic Advances Highlight DexCom's First Quarter Achievements
